Version:

02-04-2014 01-09-2017: Varicella 28-10-2021: Introduction of HPV vaccination in boys starting from 2020-21 school year 01-01-2023: 2023 vaccination calendar 01-01-2024: 2024 vaccination programme 25-06-2025: Version 2025 02-02-2026: Version 2026

Footnotes:

1. The vaccine used is about to change to PCV13 in January 2026. For more information on pneumococcal vaccination and target groups refer to https://thl.fi
2. Varicella vaccination implemented from 1 September 2017. Catch-up to all those born on 1st January 2006 or after and with no history of varicella.
3. For high risk groups: https://thl.fi
4. More information: https://thl.fi
5. For specific at risk-groups only (to be given at the earliest age) Vaccine can be given up til 7 years of age.
6. dtap-vaccine for pregnant women during every pregnancy. dtap-vaccine is also given every 5 year to health and welfare workers who are working with infants.
7. Risk-groups only.
8. For more information on pneumococcal vaccination and target groups refer to https://thl.fi
9. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote
10. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote MenB: Bexsero vaccine is administered to infants aged 2 to 5 months as a series of three doses, spaced at least one month apart. A booster dose is then recommended at 12 to 15 months of age, provided that at least six months have passed since the last dose. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
11. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
12. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
13. A MCV4 dose is administered to military conscripts upon commencement of their service (compulsory for men and voluntary for women). While the majority begin service between the ages of 19 and 20, the official age range for enlistment spans from 18 to 29 years.
14. Recommendation for the first dose to be given at 12 months of age
15. Further information available at https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/rokotteet-a-o/vesirokkorokote
16. More information available at https://thl.fi
17. 2 doses under 15 years old and 3 doses from 15 years and older.
18. For risk-groups only.
19. TBE vaccination for specific areas in Finland.

More information available at:
https://thl.fi/aiheet/infektiotaudit-ja-rokotukset


--------------------------------------------------------------------------------

MAJOR HISTORICAL CHANGES
1960: Mumps vaccinations for military recruits.
1975: Measles vaccination for 1 year old children.
1975: Rubella vaccination for 11-13 years old girls and seronegative mothers.
1982: Two doses of MMR vaccination at 14-18 months and 6 years of age were introduced in the national childhood vaccination programme.
2009: Rotavirus vaccine introduced at 2, 3 and 5 months to all children (September 2009)
2010: PCV introduced at 3, 5 and 12 months of age to all children (September 2010).
2013: HPV vaccination introduced
2017: Varicella vaccination introduced (1 Sept. 2017) at 18 months, 6 years + catch-up of all born from 1 jan 2006 or after with no history of varicella
2020-21: In school years 2020–2021 and 2021–2022, the vaccine will also be offered to boys in grades 7 to 9 (catch-up vaccinations). The oldest vaccine recipients are those born in 2005.

see https://www.thl.fi/fi/web/rokottaminen/kansallinen-rokotusohjelma/rokotusohjelman-historia

--------------------------------------------------------------------------------

Date of last update: 15 Jan. 2024

--------------------------------------------------------------------------------